孟鲁司特对中重度稳定期慢性阻塞性肺疾病的临床疗效(1)
【摘要】 目的：研究孟鲁司特对中重度稳定期慢性阻塞性肺疾病(chronic obstructive pulmonary disease，COPD)的临床治疗效果。方法：选取选取2015年1月-2017年12月本院收治的60例中重度稳定期COPD患者临床资料进行分析，按照随机对数字表法分成对照组与观察组，每组30例。对照组给予信必可都保进行治疗，观察组在对照组治疗基础上增加孟鲁司特治疗，比较两组治疗效果。结果：观察组FEV1、FEV1%、FEV1/FVC明显优于对照组，观察组呼吸困难和6-MWD评分明显优于对照组，差异均有统计学意义(P<0.05)。观察组不良反应发生率10.00%与对照组6.67%比较，差异无统计学意义(P>0.05)。结论：中重度稳定期COPD患者在常规治疗时联合孟鲁司特，疗效更为显著，值得推广应用。
【关键词】 孟鲁司特； 中重度； 稳定期； 慢性阻塞性肺疾病
Clinical Effect of Montelukast on Chronic Obstructive Pulmonary Disease in Moderate-severe Stable Period/SU Guoqiu，HE Tao，LIU Zhusheng.//Medical Innovation of China，2018，15(13)：109-111
, http://www.100md.com
【Abstract】 Objective：To study the clinical effect of Montelukast on COPD in moderate-severe stable period.Method：A total of 60 patients with moderate-severe stable period COPD in our hospital from January 2015 to December 2017 were randomly divided into control group and observation group according to table of random numbers，30 patients in each group.The control group was treated with Symbicort，and observation group was treated with Montelukast on the basis of the control group.The treatment effects were compared between the two groups.Result：After treatment，the FEV1，FEV1% and FEV1/FVC of the observation group were significantly better than those of the control group，the dyspnea and 6-MWD scores of the observation group were significantly better than those of the control group，the differences were statistically significant(P<0.05).There was no significant difference of incidence of adverse reactions between the observation group 10.00% and the control group 6.67%(P>0.05).Conclusion：The effect of conventional treatment combined with Montelukast is significant in patients with moderate-severe stable period COPD，it is worth promoting the application.
, 百拇医药
【Key words】 Montelukast； Moderate-severe； Stable period； Chronic obstructive pulmonary disease(COPD)
First-author’s address：The First People’s Hospital of Zhaoqing，Zhaoqing 526020，China
doi：10.3969/j.issn.1674-4985.2018.13.030
慢性阻塞性肺疾病(chronic obstructive pulmonary disease，COPD)患者当度过了急性发作期后，患者症状有所缓解[1]，可是，患者的肺功能仍在继续恶化，病情还会出现反复发作[2]，引起其他心肺并发症。COPD为气流受限表现特征的慢性气道炎症性疾病[3]，具有极高的患病率与病死率，临床认为COPD临床主要特征是氣道、肺实质、肺血管慢性表现出慢性炎症[4]，其中重要炎症因子为白三烯，而孟鲁司特为白三烯受体拮抗剂[5]。本次研究中，选取2015年1月-2017年12月本院收治的60例中重度稳定期COPD患者临床资料进行分析，按照随机对数字表法分成对照组与观察组，应用不同的治疗方式进行比较分析，两组患者经过治疗后现将治疗效果结论报道如下。
1 资料与方法
1.1 一般资料 选取2015年1月-2017年12月本院收治的60例中重度稳定期COPD患者临床资料进行分析，按照随机对数字表法分成对照组与观察组，每组30例。纳入标准：(1)所有研究对象均符合《慢性阻塞性肺疾病诊治指南》相关诊断标准[6]；(2)所有入选患者均为中重度稳定期COPD，严重程度为Ⅲ～Ⅳ级的COPD患者[7]。排除标准：(1)合并气急加重、发热及脓痰、中性粒细胞分类高感染表现等症状患者；(2)胸片检查有肺部感染征象的患者[8]；(3)合并其他影响肺功能疾病和严重系统疾病的患者[9]。本研究经医院伦理委员会批准，患者及家属知情本次研究情况下并签署了知情同意书。, 百拇医药(苏国秋 何涛 刘杼升)
【关键词】 孟鲁司特； 中重度； 稳定期； 慢性阻塞性肺疾病
Clinical Effect of Montelukast on Chronic Obstructive Pulmonary Disease in Moderate-severe Stable Period/SU Guoqiu，HE Tao，LIU Zhusheng.//Medical Innovation of China，2018，15(13)：109-111
, http://www.100md.com
【Abstract】 Objective：To study the clinical effect of Montelukast on COPD in moderate-severe stable period.Method：A total of 60 patients with moderate-severe stable period COPD in our hospital from January 2015 to December 2017 were randomly divided into control group and observation group according to table of random numbers，30 patients in each group.The control group was treated with Symbicort，and observation group was treated with Montelukast on the basis of the control group.The treatment effects were compared between the two groups.Result：After treatment，the FEV1，FEV1% and FEV1/FVC of the observation group were significantly better than those of the control group，the dyspnea and 6-MWD scores of the observation group were significantly better than those of the control group，the differences were statistically significant(P<0.05).There was no significant difference of incidence of adverse reactions between the observation group 10.00% and the control group 6.67%(P>0.05).Conclusion：The effect of conventional treatment combined with Montelukast is significant in patients with moderate-severe stable period COPD，it is worth promoting the application.
, 百拇医药
【Key words】 Montelukast； Moderate-severe； Stable period； Chronic obstructive pulmonary disease(COPD)
First-author’s address：The First People’s Hospital of Zhaoqing，Zhaoqing 526020，China
doi：10.3969/j.issn.1674-4985.2018.13.030
慢性阻塞性肺疾病(chronic obstructive pulmonary disease，COPD)患者当度过了急性发作期后，患者症状有所缓解[1]，可是，患者的肺功能仍在继续恶化，病情还会出现反复发作[2]，引起其他心肺并发症。COPD为气流受限表现特征的慢性气道炎症性疾病[3]，具有极高的患病率与病死率，临床认为COPD临床主要特征是氣道、肺实质、肺血管慢性表现出慢性炎症[4]，其中重要炎症因子为白三烯，而孟鲁司特为白三烯受体拮抗剂[5]。本次研究中，选取2015年1月-2017年12月本院收治的60例中重度稳定期COPD患者临床资料进行分析，按照随机对数字表法分成对照组与观察组，应用不同的治疗方式进行比较分析，两组患者经过治疗后现将治疗效果结论报道如下。
1 资料与方法
1.1 一般资料 选取2015年1月-2017年12月本院收治的60例中重度稳定期COPD患者临床资料进行分析，按照随机对数字表法分成对照组与观察组，每组30例。纳入标准：(1)所有研究对象均符合《慢性阻塞性肺疾病诊治指南》相关诊断标准[6]；(2)所有入选患者均为中重度稳定期COPD，严重程度为Ⅲ～Ⅳ级的COPD患者[7]。排除标准：(1)合并气急加重、发热及脓痰、中性粒细胞分类高感染表现等症状患者；(2)胸片检查有肺部感染征象的患者[8]；(3)合并其他影响肺功能疾病和严重系统疾病的患者[9]。本研究经医院伦理委员会批准，患者及家属知情本次研究情况下并签署了知情同意书。, 百拇医药(苏国秋 何涛 刘杼升)